UNSPSC 51313114: Chlorcyclizine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H21ClN2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NPB7A7874U, chemically known as piperazine, 1- (p-chloro-.alpha.-phenylbenzyl)-4-methyl-, monohydrochloride but more generally known as chlorcyclizine hydrochloride, which bears US NIH Compound Identifier 2710. European Medicines Agency schedules Chlorcyclizine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01212MIG.

UNSPSC 51313114 Chlorcyclizine hydrochloride is a Commodity code that in recent state and local procurement activity spans a much broader scope than the code name alone suggests — state and local health agencies are using it to tag solicitations for generic pharmaceuticals, naloxone, drug deactivation systems, and over-the-counter products supplied through authorized wholesaler networks. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Recent opportunities show state and local governments procuring pharmaceuticals in bulk for community health programs, employee health plans, and emergency response — often requiring compliance with FDA regulations, cGMP certification, Drug Supply Chain Security Act adherence, and specific insurance and bonding thresholds.

Activity is concentrated in Florida and Minnesota, with multistate scope. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, fixed-fee pricing, and a two-year initial term plus one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with products supplied through three authorized wholesalers and pricing weighted 75 percent on competitiveness. The Texas Health and Human Services Commission issued RFI HHS0017013 (April 3, 2026) seeking vendor capabilities for a direct-to-manufacturer prescription program outside traditional PBM arrangements. All three solicitations include drug-free workplace, E-Verify, and federal compliance requirements; MMCAP also mandates $5 million commercial general liability coverage and performance penalties for late reporting or missed onboarding timelines.